The study for acupoint stimulation on preventive treatment of advenocortical function inhibition induced by etomidate: a randomized, double-blind, prospective study.
- Conditions
- advenocortical function inhibition
- Registration Number
- ITMCTR2000004212
- Lead Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Patients must meet all of the following criteria for inclusion in this study:
1. Aged 18-90 years, gender unlimited;
2. ASA range from I to III grade;
3. 18 kg/m24. Clear understanding and voluntary participation in this study.
1. Patients with endocrine system diseases such as Kuxing syndrome, pituitary adenoma and adrenal tumor;
2. Patients with hormone drugs within 3 months before operation;
3. Patients with glucocorticoid drugs intraoperatively and postoperatively;
4. Asthma patients;
5. Severe respiratory diseases (obstructive sleep apnea syndrome, acute respiratory infection, acute attack of chronic obstructive pulmonary disease, uncontrolled asthma, active massive hemoptysis, severe pulmonary hypertension, etc);
6. Acute heart failure; unstable angina pectoris; myocardial infarction within 6 months before screening; resting electrocardiogram heart rate < 50 beats / min; third degree atrioventricular block; severe arrhythmia; moderate and severe valvular disease; QTc: male >= 450 ms, female >= 470ms; patients with aortic aneurysm;
7. Infectious heart diseases such as myocarditis or endocarditis; septicemia;
8. People with mental system diseases (schizophrenia, mania, bipolar disorder, insanity, etc.) and long-term history of taking psychotropic drugs and cognitive impairment;
9. Anemia or thrombocytopenia: Hb < 90g/L; PLT < 80x10^9/L;
10. Dysfunction of blood coagulation: PT > ULN +3s and/or APTT > ULN+10s;
11. Liver dysfunction: AST and/or ALT >= 2.5 x ULN, TBIL >= 1.5 x ULN;
12. Renal dysfunction: urea or urea nitrogen >= 1.5x ULN, serum creatinine greater than the upper limit of normal value;
13. There was a history of substance abuse, drug abuse and alcohol abuse within two years prior to the screening period, with alcohol consumption, i.e. drinking more than 2 units of alcohol per day on average (1 unit =360 ml beer or 45 ml liquor with 40% alcohol or 150 wine);
14. Patients who did not receive regular hypotension or have poor blood pressure control (sitting systolic blood pressure >= 160 mmHg or 90 mmHg, and / or 100 mmHg diastolic blood pressure during screening);
15. Patients whose blood glucose was not satisfactorily controlled (random blood glucose >= 11.1 mmol/l);
16. Allergic or contraindicated drugs such as benzodiazepines, opioids, etomidate, propofol and their components;
17. Patients identified as having difficulties in respiratory management (modified Mallampati ? grade);
18. Participated in any clinical drug trial and used the trial drug as a subject in the last 3 months;
19. Patients who could undergo adrenal surgery;
20. Contraindications of trauma and infection in acupuncture and moxibustion puncture site;
21. Other factors that may interfere with the results.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Concentration of Serum cortisol;
- Secondary Outcome Measures
Name Time Method Duration of staying in PACU;Postoperation nausea and vomitting times;Incidence of fever;Excessive sedation;Chalder fatigue rating scaleChiari;Duration of patients' consciousness recovery;Postoperative recovery time of gastrointestinal function;Duration of Tracheal tube withdrawal;POCD;